[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-disease-on-hemodialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-disease-on-hemodialysis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,84,109,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100643246","reference-values-for-lower-limb-dynamometry-in-patients-with-chronic-kidney-disease-rehad-ckd-100643246",false,"NCT07642778","Reference Values for Lower-Limb Dynamometry in Patients With Chronic Kidney Disease (REHAD-CKD)","REHAD- CKD","Inclusion Criteria:\n\n* ≥1 months on HD (3 weekly sessions of 4 hours)\n\nExclusion Criteria:\n\n* Lower-limb amputation;\n* Neurological, musculoskeletal or osteoarticular disorders;\n* Severe\u002Funstable comorbidities (e.g., decompensated heart failure or diabetes, unstable angina, recent MI, uncontrolled hypertension, severe lung disease, acute infection);\n* \\\u003C1 months on HD;\n* \\\u003C2 sessions\u002Fweek,\n* Inability to understand assessments.","ALL","18 Years","85 Years",{"count":20,"type":21},50,"ESTIMATED","6 Weeks","OBSERVATIONAL","Patients with chronic kidney disease (CKD) undergoing hemodialysis present musculoskeletal complications, such as sarcopenia, which impair their functionality and are associated with an increased risk of mortality. Functional assessment in this population is complex due to the organization of hemodialysis schedules and patients' dependence on medical transportation, which hinders evaluation outside the dialysis setting.\n\nThe assessment of lower limb strength is of great relevance, as an adequate level of muscle strength in this region is essential for performing many activities of daily living, including walking, sit-to-stand and stand-to-sit movements, as well as ascending and descending stairs. Our research group has published a study demonstrating the safety and reliability of intradialytic measurement of hip flexion and abduction strength; however, reference values for the dialysis population and for individuals with CKD in general are currently unknown.\n\nThe primary aim of this study is to propose reference values for hip flexor and abductor muscle strength measured using a hand-held dynamometer in individuals with chronic kidney disease (CKD). Secondary objectives include assessing the association between lower limb muscle strength measured with a hand-held dynamometer and handgrip strength, physical activity level, frailty, gait speed, performance in the 10-repetition sit-to-stand-to-sit test, ultrasound assessment of the rectus femoris muscle, and health-related quality of life.",[26],"Chronic Kidney Disease on Hemodialysis",[28,29,30],"Chronic Kidney Disease","Lower limb strength","Intradialytic assessment","RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-12","ACTUAL",{"date":37,"type":21},"2026-10",{"date":39,"type":21},"2026-12",{"name":41,"class":42},"Cardenal Herrera University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":43},"100619739","expanded-hemodialysis-versus-high-volume-online-hemodiafiltration-for-uremic-toxin-removal-100619739","NCT07348536","Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal","Impact of Expanded Hemodialysis Prescription on Global Uremic Toxin Removal Compared With High-Volume Online Hemodiafiltration: A Randomized Open-Label Crossover Study","REMOV-HDx","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End stage renal disease Receiving maintenance hemodialysis three times per week on expanded hemodialysis as part of routine care for at least 1 month\n* On dialysis treatment for more than 3 months\n* Minimal or no residual urine output (less than 100 mL per day)\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Vascular access unable to support a blood flow of at least 300 mL\u002Fmin",{"count":53,"type":21},15,"INTERVENTIONAL",[56],"NA","People with advanced kidney disease need dialysis to remove waste products from the blood. Some of these waste products, called uremic toxins, are small, while others are medium-sized and more difficult to remove. Poor removal of these toxins may contribute to symptoms and long-term complications in patients on dialysis.\n\nTwo dialysis techniques are commonly used to improve toxin removal beyond standard hemodialysis: expanded hemodialysis (HDx) using medium cut-off membranes, and high-volume online hemodiafiltration (HV-OL-HDF). Although both techniques are effective, the best way to prescribe expanded hemodialysis-particularly the ideal treatment time-has not been clearly defined.\n\nThe purpose of this study is to compare how well different treatment times of expanded hemodialysis remove small and medium-sized uremic toxins, and to compare these results with high-volume online hemodiafiltration. Toxin removal will be evaluated using a combined measurement called the Global Removal Score, which summarizes the removal of several important waste substances.\n\nThis is a single-center, randomized, open-label, crossover study. Adults receiving maintenance hemodialysis will receive three different expanded hemodialysis sessions with different treatment durations (180, 210, and 240 minutes), followed by one session of high-volume online hemodiafiltration. Blood samples will be taken before and after each dialysis session to measure toxin levels.\n\nThe results of this study may help determine whether expanded hemodialysis with shorter or standard treatment times can achieve toxin removal similar to high-volume hemodiafiltration, which could support more personalized and practical dialysis prescriptions.",[59,26,60,61,62,63],"End Stage Renal Disease (ESRD)","Renal Dialysis","Uremia; Chronic","Hemodialysis","Hemodiafiltration",[65,66,67,68,69,70,71,72,73],"Expanded hemodialysis","High-volume online hemodiafiltration","Medium cut-off dialysis membranes","Uremic toxin removal","Middle molecule clearance","Chronic kidney failure","Dialysis dose optimization","Dialysis treatment time","Global removal score","NOT_YET_RECRUITING","2026-03-23",{"date":77,"type":35},"2026-03-24",{"date":79,"type":21},"2026-04",{"date":81,"type":21},"2029-12",{"name":83,"class":42},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":92,"targetDuration":94,"studyType":23,"phases":4,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100629448","outcomes-of-renal-replacement-in-mexico-100629448","NCT07474805","Outcomes of Renal Replacement in Mexico","Clinical Outcomes Study of Mexican Patients With Chronic Kidney Disease on Renal Replacement Therapy","ORReMex","Inclusion Criteria:\n\n* Willingness to participate and provision of written informed consent\n* Diagnosis of chronic kidney disease and treatment with hemodialysis or peritoneal dialysis for ≥3 months\n* Availability of a medical record containing information on the study variables\n* Receiving care at one of the participating centers\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C3 months due to a cause unrelated to chronic kidney disease",{"count":93,"type":21},290,"3 Years","A descriptive, observational, prospective, multicenter study aimed at describing the main clinical outcomes of patients with chronic kidney disease receiving any form of renal replacement therapy in Mexico.",[97,26],"Chronic Kidney Disease - Stage V",[99,100,101],"Chronic kidney disease","Renal replacement therapy","Clinical outcomes","2026-03-12",{"date":104,"type":35},"2026-03-16",{"date":79,"type":21},{"date":107,"type":21},"2029-04",{"name":83,"class":42},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":54,"phases":119,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100572662","phase-4-the-cardioprotective-effects-of-improving-potassium-variability-in-maintenance-hemodialysis-patients-100572662","NCT06736184","the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients","A Prospective Multicenter Randomized Controlled Trial on the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients","Inclusion Criteria:\n\n1. Age 18-75 years old;\n2. Maintenance hemodialysis ≥3 months;\n3. Serum potassium ≥5.0mmol\u002FL and ≤8mmol\u002FL before dialysis;\n4. Have independent ability;\n5. Complete clinical baseline data.\n\nExclusion Criteria:\n\n1. Complicated with congenital heart disease, myocardial infarction and other heart diseases that may lead to cardiac dysfunction;\n2. Combined with other serious diseases, such as immune diseases, severe liver and kidney dysfunction;\n3. Unable to cooperate with the researcher due to mental reasons;\n4. If the duration of dialysis is less than 4 hours, severe infection;\n5. Patients with malignant tumors or major mental disorders;\n\n6, except primary cardiomyopathy;\n\n7\\. Severe constipation, intestinal obstruction, etc.\n\n8\\. other investigators considered that enrollment was not recommended.","75 Years",{"count":118,"type":21},100,[120],"PHASE4","The management of serum potassium in maintenance hemodialysis（MHD ）patients is one of the hot topics at present. In order to control hyperkalemia in dialysis patients, the use of hypokalemic dialysate is the most important measure to reduce potassium. This measure effectively reduces serum potassium, but increases the risk of hypokalemia after dialysis, which increases the risk of all-cause death in patients. Hyperkalemia and hypokalemia during and at the end of dialysis are important factors for arrhythmia and death in MHD patients. Due to the intermittent nature of hemodialysis treatment, MHD patients often experience frequent fluctuations in serum potassium, which is a potential risk factor for poor prognosis of MHD patients. Serum potassium variability can better reflect the potassium homeostasis in MHD patients. In addition to hyperkalemia and hypokalemia, serum potassium variability is a potential risk factor affecting the prognosis of MHD patients. At present, there are few studies on the effect of improving serum potassium variability on cardiovascular complications, especially multi-center randomized controlled trials. In this study, sodium zirconium cyclosilicate was used to control hyperkalemia before dialysis and increase potassium concentration in dialysate, so as to reduce the risk of hypokalemia after dialysis, and to verify whether improving serum potassium variability can reduce myocardial injury in hemodialysis patients.",[26,123,124,125],"Hypokalemia","Hyperkalemia","Myocardial Injury",[127,128,129],"maintenance hemodialysis","Potassium Variability","Myocardial injury","2024-12-12",{"date":132,"type":35},"2024-12-16",{"date":134,"type":21},"2025-03-01",{"date":136,"type":21},"2026-12-31",{"name":138,"class":42},"Qianfoshan Hospital",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":54,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":43},"100561280","arteriovenous-fistula-cannulation-pain-and-skin-cooling-device-100561280","NCT06588114","Arteriovenous Fistula Cannulation Pain and Skin Cooling Device","Antistress Ball Applied to Hemodialysis Patients, Valsalva Maneuver and Pain Due to Arteriovenous Fistula Cannulation of Skin Cooling Device and the Effect of Fear of Pain: a Randomized Controlled Trial","HD patients","Inclusion Criteria:\n\n* be 18 years of age or older\n* Volunteering to participate in the study\n* Being a hemodialysis patient and being on hemodialysis for more than three months\n* Having an arteriovenous fistula that has been used for more than a month\n* To be hemodialyzed three times a week\n* To be literate\n* Absence of communication barrier\n* Not having any psychiatric diagnosis\n* Not having cognitive impairment\n\nExclusion Criteria:\n\n* being under the age of 18\n* It takes less than a month for the arteriovenous fistula to be newly opened\n* Having a different type of vascular interference from arteriovenous fistula\n* Having phlebitis, scar tissue, dermatitis, an incision or infection at the site of arteriovenous interference\n* Hemodialysis of the patient more or less than three times a week\n* Having any disease that may affect the perception of pain\n* Illiteracy\n* Having a psychiatric diagnosis\n* Having any discomfort in the hand and arm that allows squeezing the antistress ball\n* There is a communication barrier\n* Having a cognitive impairment",{"count":148,"type":21},60,[56],"To determine the effect of the antistress ball, valsalva maneuver and skin cooling device, which are one of the nonpharmacological methods applied to hemodialysis patients, on the level of pain and fear of pain due to arteriovenous fistula cannulation.",[26],[62,153,154,155],"Arteriovenous fistula","Valsalva","Antistress ball","2024-09-05",{"date":158,"type":35},"2024-09-19",{"date":160,"type":21},"2024-10-01",{"date":162,"type":21},"2024-12-01",{"name":164,"class":42},"Karadeniz Technical University"]